The archive doesn't contain a direct discussion of clinical validation strategies for fertility tech startups. What emerges instead is the market pressure that drives evidence-gathering: fertility services have high failure rates (75% for artificial insemination, 25% for certain procedures [Ep 40]), and NHS organisations require rigorous proof of efficacy before adoption [Ep 26].
The practical path appears to be market-first: founders enter different markets, accumulate real-world data, and build the evidence case for NHS adoption [Ep 26]. One investor notes that fertility is "ripe for investment" precisely because innovation is addressing latent clinical need—rising infertility rates and declining male sperm counts over decades [#112]. The startups in the archive focus on reducing clinician burden (home-based care, better sperm selection, embryo assessment automation [#340][Ep 40]) rather than unproven biology, which suggests evidence builds around demonstrated clinical utility rather than novel mechanisms.
A sharper question would be: what specific regulatory pathways (CE marking, CLIA, FDA) are fertility startups using, and how do timelines differ by market?
Search 450+ episodes and 42,000 chunks of healthtech conversation.